

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/681,855
Filing Date	October 7, 2003
First Named Inventor	BEDNARSKI <i>et al.</i>
Art Unit	1614
Examiner Name	James D. ANDERSON
Attorney Docket Number	067425-5001-US (Formerly RADO-001/02US)

Sheet	1	of	2
-------	---	----	---

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Citeq No.	U.S. Patent Document Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	5,580,988 A	12-03-1996	Dave	
	A2	6,245,799 B1	06-12-2001	Asselin <i>et al.</i>	
	A3	6,407,236 B1	06-18-2002	Baraldi <i>et al.</i>	
	A4	US 2004/0024057	02-05-2004	Earl <i>et al.</i>	
	A5				
	A6				
	A7				
	A8				
	A9				
	A10				
	A11				
	A12				
	A13				

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Citeq No.	Foreign Patent Document Country Code* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†*
	A14	WO 2004/098538	11-18-2004	Nitromed, Inc.		
	A15	WO 2004/113281	12-29-2004	JE IL Pharmaceutical Co., Ltd.		
	A16	WO 2007/022121	02-22-2007	ATK Thiokol Propulsion Inc.		
	A17	WO 2007/022225	02-22-2007	ATK Thiokol Propulsion Inc.		
	A18					

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Citeq No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	†*
	A19	HUGUENIN <i>et al.</i> , "Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines", Cancer Letters 218 (2005), 163-170 (Abstract, pgs. 165,169)	
	A20	NAIMI <i>et al.</i> , "Synthesis of 3'- and 5'-Nitrooxy Pyrimidine Nucleoside Nitrate Esters: 'Nitric Oxide Donor' Agents for Evaluation as Anticancer and Antiviral Agents", J. Med. Chem. (2003), (Abstract, pgs. 46,995-1004)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP §01.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.